94 related articles for article (PubMed ID: 24638068)
21. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
22. The D-6 mouse monoclonal antibody recognizes the CD74 cytoplasmic tail.
Genève L; Gauthier C; Thibodeau J
Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):221-7. PubMed ID: 25171001
[TBL] [Abstract][Full Text] [Related]
23. The intracellular localization and oligomerization of chicken invariant chain with major histocompatibility complex class II subunits.
Ye H; Xu FZ; Yu WY
Poult Sci; 2009 Aug; 88(8):1594-600. PubMed ID: 19590073
[TBL] [Abstract][Full Text] [Related]
24. The p35 human invariant chain in transgenic mice restores mature B cells in the absence of endogenous CD74.
Genève L; Ménard C; Labrecque N; Thibodeau J
Int Immunol; 2012 Oct; 24(10):645-60. PubMed ID: 22966065
[TBL] [Abstract][Full Text] [Related]
25. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
26. Exit of major histocompatibility complex class II-invariant chain p35 complexes from the endoplasmic reticulum is modulated by phosphorylation.
Kuwana T; Peterson PA; Karlsson L
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1056-61. PubMed ID: 9448284
[TBL] [Abstract][Full Text] [Related]
27. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
28. Invariant chain is a new chaperone for TLR7 in B cells.
Tohmé M; Manoury B
Mol Immunol; 2015 Dec; 68(2 Pt A):102-5. PubMed ID: 26198699
[TBL] [Abstract][Full Text] [Related]
29. Revisiting the structural basis and energetic landscape of susceptibility difference between HLA isotypes to allergic rhinitis.
Mao XL; Zhu F; Pan ZH; Wu GM; Zhu HY
Comput Biol Chem; 2016 Oct; 64():210-216. PubMed ID: 27433817
[TBL] [Abstract][Full Text] [Related]
30. MHC II and the endocytic pathway: regulation by invariant chain.
Landsverk OJ; Bakke O; Gregers TF
Scand J Immunol; 2009 Sep; 70(3):184-93. PubMed ID: 19703008
[TBL] [Abstract][Full Text] [Related]
31. Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo.
Newcomb JR; Cresswell P
J Immunol; 1993 Oct; 151(8):4153-63. PubMed ID: 8409392
[TBL] [Abstract][Full Text] [Related]
32. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing.
Zhou Z; Reyes-Vargas E; Escobar H; Chang KY; Barker AP; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2017 Feb; 47(2):314-326. PubMed ID: 27861808
[TBL] [Abstract][Full Text] [Related]
33. Regulation of HLA-DR and invariant chain expression by human peripheral blood mononuclear cells with lead, interferon-gamma, or interleukin-4.
Guo TL; Mudzinski SP; Lawrence DA
Cell Immunol; 1996 Jul; 171(1):1-9. PubMed ID: 8660831
[TBL] [Abstract][Full Text] [Related]
34. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
35. A conserved WW domain-like motif regulates invariant chain-dependent cell-surface transport of the NKG2D ligand ULBP2.
Uhlenbrock F; van Andel E; Andresen L; Skov S
Mol Immunol; 2015 Aug; 66(2):418-27. PubMed ID: 25983110
[TBL] [Abstract][Full Text] [Related]
36. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain.
Hansson GK; Jonasson L; Holm J; Claesson-Welsh L
Clin Exp Immunol; 1986 May; 64(2):261-8. PubMed ID: 3527502
[TBL] [Abstract][Full Text] [Related]
37. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
Bertolino P; Rabourdin-Combe C
Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
[TBL] [Abstract][Full Text] [Related]
38. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer.
Jo YS; Lee JC; Li S; Choi YS; Bai YS; Kim YJ; Lee IS; Rha SY; Ro HK; Kim JM; Shong M
Int J Cancer; 2008 Feb; 122(4):785-90. PubMed ID: 17957790
[TBL] [Abstract][Full Text] [Related]
39. Assembly of major histocompatibility complex class II subunits with invariant chain.
Neumann J; Koch N
FEBS Lett; 2005 Nov; 579(27):6055-9. PubMed ID: 16242130
[TBL] [Abstract][Full Text] [Related]
40. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
